# US 2022/0275397 A1 · Adenovirus polynucleotides and polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0275397 A1
- Document ID: US20220275397A1
- Status: Published application
- Kind: A1
- Application number: 17/742,221
- Filed: 2022-05-11
- Published: 2022-09-01
- Earliest claimed: 2016-12-09
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals SA
- Inventors: Virginia AMMENDOLA; Stefania CAPONE; Stefano COLLOCA; Antonella FOLGORI; Rossella MERONE
- Web page: https://patentgrep.com/patent/US20220275397A1

## CPC

- C12N 15/86: Viral vectors
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- C07K 14/005: from viruses
- A61K 2039/572: {cytotoxic response}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

## Claims

### Claim 1

An isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, and
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1.

### Claim 2

A recombinant polynucleotide comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO: 1, and
(b) a polynucleotide which encodes a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1.

### Claim 3

A recombinant vector comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO: 1, and
(b) a polynucleotide which encodes a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1.

### Claim 4

A recombinant adenovirus comprising at least one polynucleotide or polypeptide selected from the group consisting of:
(a) a polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO: 1,
(b) a polynucleotide which encodes a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1,
(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, and
(d) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1.

### Claim 5 (depends on 3, 4)

A composition comprising at least one of the following:
(a) a polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO: 1,
(b) a polynucleotide which encodes a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1,
(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 1,
(d) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1,
(e) a vector according to claim 3, and
(f) a recombinant adenovirus according to claim 4,
and a pharmaceutically acceptable excipient.

### Claim 6 (depends on 3, 4)

A cell comprising at least one of the following:
(a) a polynucleotide which encodes a polypeptide having the amino acid sequence according to SEQ ID NO: 1,
(b) a polynucleotide which encodes a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1,
(c) a polypeptide having the amino acid sequence according to SEQ ID NO: 1,
(d) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1,
(e) a vector according to claim 3, and
(f) a recombinant adenovirus according to claim 4.

### Claim 7

An isolated adenoviral polypeptide selected from the group consisting of:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, and
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 6, wherein the polynucleotide encodes a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 99.8% identical over its entire length to the amino acid sequence of SEQ ID NO: 1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 6, wherein the polynucleotide encodes a polypeptide having the amino acid sequence according to SEQ ID NO: 1.

### Claim 10 (depends on 9)

The polynucleotide, vector, adenovirus, composition or cell according to claim 9, wherein the polynucleotide has a sequence according to SEQ ID NO: 2.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 10, further comprising a polynucleotide encoding:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 3; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 3, wherein the functional derivative has an amino acid sequence which is at least 60% identical over its entire length to the amino acid sequence of SEQ ID NO: 3,
or
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 5; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 5, wherein the functional derivative has an amino acid sequence which is at least 60% identical over its entire length to the amino acid sequence of SEQ ID NO: 5.

### Claim 12 (depends on 11)

The polynucleotide, vector, adenovirus, composition or cell according to claim 11, further comprising a polynucleotide encoding:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 3; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 3, wherein the functional derivative has an amino acid sequence which is at least 98% identical over its entire length to the amino acid sequence of SEQ ID NO: 3,
or
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 5; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 5, wherein the functional derivative has an amino acid sequence which is at least 98% identical over its entire length to the amino acid sequence of SEQ ID NO: 5.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 10, further comprising a polynucleotide encoding:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 3; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 3, wherein the functional derivative has an amino acid sequence which is at least 98% identical over its entire length to the amino acid sequence of SEQ ID NO: 3,
and
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 5; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 5, wherein the functional derivative has an amino acid sequence which is at least 98% identical over its entire length to the amino acid sequence of SEQ ID NO: 5.

### Claim 14 (depends on 13)

The polynucleotide, vector, adenovirus, composition or cell according to claim 13, further comprising a polynucleotide encoding:
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 3; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 3, wherein the functional derivative has an amino acid sequence which is at least 98% identical over its entire length to the amino acid sequence of SEQ ID NO: 3,
and
(a) a polypeptide having the amino acid sequence according to SEQ ID NO: 5; or
(b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 5, wherein the functional derivative has an amino acid sequence which is at least 98% identical over its entire length to the amino acid sequence of SEQ ID NO: 5.

### Claim 15 (depends on 11, 12, 13, 14)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 11 to 14, wherein the polynucleotide comprises a sequence according to SEQ ID NO: 4.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The polynucleotide, vector, adenovirus, composition or cell according to claim any one of claims 11 to 15, wherein the polynucleotide comprises a sequence according to SEQ ID NO: 6.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 16, wherein the polynucleotide comprises at least one of the following:
(a) an adenoviral 5′-end, preferably an adenoviral 5′ inverted terminal repeat;
(b) an adenoviral EIA region, or a fragment thereof selected from among the E1A_280R and E1A_243R regions;
(c) an adenoviral EIB or IX region, or a fragment thereof selected from among the group consisting of the E1B_19K, E1B_55K or IX regions;
(d) an adenoviral E2b region; or a fragment thereof selected from among the group consisting of the E2B_pTP, E2B_Polymerase and E2B_IVa2 regions;
(e) an adenoviral L1 region, or a fragment thereof, said fragment encoding an adenoviral protein selected from the group consisting of the L1_13.6 k protein, L1_52 k and L1_IIIa protein;
(f) an adenoviral L2 region, or a fragment thereof, said fragment encoding an adenoviral protein selected from the group consisting of the L2_penton protein according to claim 3, L2_pVII, L2_V, and L2_pX protein;
(g) an adenoviral L3 region, or a fragment thereof, said fragment encoding an adenoviral protein selected from the group consisting of the L3_pVI protein, L3_hexon protein according to claim 2 and L3_protease;
(h) an adenoviral E2A region;
(i) an adenoviral L4 region, or a fragment thereof said fragment encoding an adenoviral protein selected from the group consisting of the L4_100 k protein, the L4_33 k protein and protein L4_VIII;
(j) an adenoviral E3 region, or a fragment thereof selected from the group consisting of E3 ORF1, E3 ORF2, E3 ORF3, E3 ORF4, E3 ORF5, E3 ORF6, E3 ORF7, E3 ORF8, and E3 ORF9;
(k) an adenoviral L5 region, or a fragment thereof said fragment encoding the L5_fiber protein according to claim 1;
(1) an adenoviral E4 region, or a fragment thereof selected from the group consisting of E4 ORF7, E4 ORF6, E4 ORF4, E4 ORF3, E4 ORF2, and E4 ORF1;
(m) an adenoviral 3′-end, preferably an adenoviral 3′ inverted terminal repeat; and/or
(n) an adenoviral VAI or VAII RNA region, preferably an adenoviral VAI or VAII RNA region from an adenovirus other than ChAd157, more preferably from Ad5.

### Claim 18 (depends on 1, 2, 3, 17)

The polynucleotide, vector, adenovirus, composition or cell according to claim 17, wherein the polynucleotide comprises at least one of the following:
(a) an adenoviral 5′-end, preferably an adenoviral 5′ inverted terminal repeat;
(e) an adenoviral L1 region, or a fragment thereof, said fragment encoding an adenoviral protein selected from the group consisting of the L1_13.6 k protein, L1_52 k and L1_IIIa protein;
(f) an adenoviral L2 region, or a fragment thereof, said fragment encoding an adenoviral protein selected from the group consisting of the L2_penton protein according to claim 3, L2_pVII, L2_V, and L2_pX protein;
(g) an adenoviral L3 region, or a fragment thereof, said fragment encoding an adenoviral protein selected from the group consisting of the L3_pVI protein, L3_hexon protein according to claim 2 and L3_protease;
(i) an adenoviral L4 region, or a fragment thereof said fragment encoding an adenoviral protein selected from the group consisting of the L4_100 k protein, the L4_33 k protein and protein L4_VIII;
(k) an adenoviral L5 region, or a fragment thereof said fragment encoding the L5_fiber protein according to claim 1;
(m) an adenoviral 3′-end, preferably an adenoviral 3′ inverted terminal repeat.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 16, wherein the polynucleotide comprises an adenoviral VAI or VAII RNA region.

### Claim 20 (depends on 19)

The polynucleotide, vector, adenovirus, composition or cell according to claim 19, wherein the VAI or VAII RNA region is from an adenovirus other than ChAd157.

### Claim 21 (depends on 20)

The polynucleotide, vector, adenovirus, composition or cell according to claim 20, wherein the VAI or VAII RNA region is from Ad5.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 16, wherein the polynucleotide comprises or consists of a polynucleotide which is at least 95% identical over its entire length to a reference sequence that consists essentially of SEQ ID NO: 15 or 22.

### Claim 23 (depends on 22)

The polynucleotide, vector, adenovirus, composition or cell according to claim 22, wherein the polynucleotide comprises or consists of a polynucleotide which is at least 99% identical over its entire length to the reference sequence.

### Claim 24 (depends on 23)

The polynucleotide, vector, adenovirus, composition or cell according to claim 23, wherein the polynucleotide comprises or consists of a polynucleotide which is at least 99.5% identical over its entire length to the reference sequence.

### Claim 25 (depends on 22, 23, 24)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 22 to 24, wherein the polynucleotide comprises or consists of a polynucleotide which is identical over its entire length to the reference sequence.

### Claim 26 (depends on 25)

The polynucleotide, vector, adenovirus, composition or cell according to claim 25, wherein the reference sequence is SEQ ID NO: 15.

### Claim 27 (depends on 25)

The polynucleotide, vector, adenovirus, composition or cell according to claim 25, wherein the reference sequence is SEQ ID NO: 22.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 16, wherein the polynucleotide comprises a mutation or deletion which renders non-functional at least one gene of a genomic region selected from the group consisting of E1A, E1B, E2A, E2B, E3 and E4.

### Claim 29 (depends on 28)

The polynucleotide, vector, adenovirus, composition or cell according to claim 28, wherein the polynucleotide lacks at least one gene of a genomic region selected from the group consisting of E1A, E1B, E2A, E2B, E3 and/or E4.

### Claim 30 (depends on 28, 29)

The polynucleotide, vector, adenovirus, composition or cell according to either claim 28 or 29, wherein the genomic regions are E1A and/or E1B.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The polynucleotide, vector, adenovirus, composition or cell according to any one of claims 1 to 16, wherein the polynucleotide comprises a deletion of the E1 genomic region.

### Claim 32 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The adenovirus according to any one of claims 4 and 8 to 31, wherein the recombinant adenovirus is replication-competent.

### Claim 33 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The adenovirus according to any one of claims 4 and 8 to 32, wherein the recombinant adenovirus is replication-incompetent.

### Claim 34 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The adenovirus of any one of claims 4 and 8 to 33, wherein the recombinant adenovirus comprises a nucleic acid sequence encoding a protein, wherein the nucleic acid sequence is operatively linked to one or more sequences which direct expression of said protein in a host cell.

### Claim 35 (depends on 34)

The adenovirus according to claim 34, wherein the protein is an antigenic protein or a fragment thereof.

### Claim 36 (depends on 35)

The adenovirus according to claim 35 wherein the protein is a heterologous protein or fragment thereof.

### Claim 37 (depends on 36)

The adenovirus of claim 36, wherein the protein is derived from a virus.

### Claim 38 (depends on 34, 35, 36, 37)

The adenovirus of any one of claims 34 to 37, wherein the one or more sequences which direct expression of said product in a host cell includes a sequence selected from one or more of the group consisting of: transcription initiation, transcription termination, promoter and enhancer sequences.

### Claim 39 (depends on 38)

The adenovirus of claim 38, wherein the one or more sequences which direct expression of said product in a host cell includes a promoter sequence.

### Claim 40 (depends on 39)

The adenovirus of claim 39, wherein the promoter sequence is selected from the group consisting of an internal promoter, a native promoter, RSV LTR promoter, CMV promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, PGK promoter, EF1 a promoter and CASI promoter.

### Claim 41 (depends on 39)

The adenovirus of claim 39, wherein the promoter sequence is an enhanced hCMV promoter, such as provided in SEQ ID NO: 42.

### Claim 42 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The adenovirus according to any one of claims 4 and 8 to 41, wherein the adenovirus has a seroprevalence of less than 10% in human subjects and preferably no seroprevalence in human subjects.

### Claim 43 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The adenovirus according to any one of claims 4 and 8 to 42, wherein the adenovirus is capable of infecting a mammalian cell.

### Claim 44 (depends on 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The composition according to any one of claims 5 and 8 to 43, comprising an adjuvant selected from the list consisting of: inorganic adjuvants (e.g. inorganic metal salts such as aluminium phosphate or aluminium hydroxide), organic adjuvants (e.g. saponins, such as QS21, or squalene), oil-based adjuvants (e.g. Freund's complete adjuvant and Freund's incomplete adjuvant), cytokines (e.g. IL-1β, IL-2, IL-7, IL-12, IL-18, GM-CFS, and INF-γ) particulate adjuvants (e.g. immuno-stimulatory complexes (ISCOMS), liposomes, or biodegradable microspheres), virosomes, bacterial adjuvants (e.g. monophosphoryl lipid A, such as 3-de-O-acylated monophosphoryl lipid A (3D-MPL), or muramyl peptides), synthetic adjuvants (e.g. non-ionic block copolymers, muramyl peptide analogues, or synthetic lipid A), synthetic polynucleotides adjuvants (e.g polyarginine or polylysine) and immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides (“CpG”).

### Claim 45 (depends on 44)

The composition according to claim 44, wherein the adjuvant is a 3D-MPL and/or QS21.

### Claim 46 (depends on 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The cell according to any one of claims 6 and 8 to 31, wherein the cell is a host cell that expresses at least one adenoviral gene selected from the group consisting of E1A, E1B, E2A, E2B, E3 E4, L1, L2, L3, L4 and L5.

### Claim 47 (depends on 45)

The cell according to claim 45 wherein the host cell is grown in suspension.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A polynucleotide, polypeptide, vector, adenovirus, composition or cell according to any one of claims 1 to 47, for use as a medicament.

### Claim 49 (depends on 48)

A polynucleotide, polypeptide, vector, adenovirus, composition or cell according to claim 48, for use as a vaccine.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

Use of the polynucleotide, polypeptide, vector, adenovirus, composition or cell according to any one of claims 1 to 47 for the therapy or prophylaxis of a disease.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A method of inducing an immune response in a subject comprising administering the polynucleotide, polypeptide, vector, adenovirus, composition or cell according to any one of claims 1 to 47 to the subject.

### Claim 52

An isolated polynucleotide comprising or consisting of the sequence according to SEQ ID NO: 2.

### Claim 53 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene for administration to a subject which has previously been exposed to a recombinant adenoviral vector which does not comprise a ChAd157 fiber, or functional derivative thereof, as described herein.

### Claim 54 (depends on 53)

The recombinant adenoviral vector according to claim 53, wherein the subject which has previously been exposed to a recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton.

### Claim 55 (depends on 54)

The recombinant adenoviral vector according to claim 54, wherein the subject which has previously been exposed to a recombinant adenoviral vector comprising a ChAd155 fiber, hexon and penton.

### Claim 56 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 54, 55)

The recombinant adenoviral vector according to claim 54 or 55, wherein the recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton encodes a transgene directed at a different medical indication or indications to the recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene.

### Claim 57 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 54, 55)

The recombinant adenoviral vector according to claim 54 or 55, wherein the recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton encodes a transgene directed at the same medical indication or indications to the recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene.

### Claim 58 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 54, 55)

The recombinant adenoviral vector according to claim 54 or 55, wherein the recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton encodes the same transgene as to the recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene.

### Claim 59 (depends on 53, 54, 55, 56, 57, 58)

The recombinant adenoviral vector according to any one of claims 53 to 58, wherein the transgenes encode an immunogen which are useful to immunize a human or non-human animal against a pathogen such as bacteria, fungi, parasitic microorganisms or multicellular parasites which infect human and non-human vertebrates, or against a cancer cell or tumor cell.

### Claim 60 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene for administration to a subject which may subsequently be exposed to a recombinant adenoviral vector which does not comprise a ChAd157 fiber, or functional derivative thereof, as described herein.

### Claim 61 (depends on 60)

The recombinant adenoviral vector according to claim 60, wherein the subject which may subsequently be exposed to a recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton.

### Claim 62 (depends on 61)

The recombinant adenoviral vector according to claim 61, wherein the subject which may subsequently be exposed to a recombinant adenoviral vector comprising a ChAd155 fiber, hexon and penton.

### Claim 63 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 61, 62)

The recombinant adenoviral vector according to claim 61 or 62, wherein the recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton encodes a transgene directed at a different medical indication or indications to the recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene.

### Claim 64 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 61, 62)

The recombinant adenoviral vector according to claim 61 or 62, wherein the recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton encodes a transgene directed at the same medical indication or indications to the recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene.

### Claim 65 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 61, 62)

The recombinant adenoviral vector according to claim 61 or 62, wherein the recombinant adenoviral vector comprising a ChAd155 fiber, hexon and/or penton encodes the same transgene as the recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a transgene.

### Claim 66 (depends on 60, 61, 62, 63, 64, 65)

The recombinant adenoviral vector according to any one of claims 60 to 65, wherein the transgenes encode an immunogen which are useful to immunize a human or non-human animal against a pathogen such as bacteria, fungi, parasitic microorganisms or multicellular parasites which infect human and non-human vertebrates, or against a cancer cell or tumor cell.

### Claim 67 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A method for eliciting an immune response in a subject, said method comprising:
(a) administering to the subject a recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a first transgene; and
(b) administering to the subject a recombinant adenoviral vector which does not comprise a ChAd157 fiber, the vector encoding a second transgene;
wherein steps (a) and (b) may be undertaken in either order and the first and second transgenes may be the same or different.

### Claim 68 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A method for the prophylaxis or treatment of a subject, said method comprising:
(a) administering to the subject a recombinant adenoviral vector according to any one of claims 4 and 8 to 43 encoding a first transgene encoding an immunogen which is useful to immunize a human or non-human animal against a pathogen such as bacteria, fungi, parasitic microorganisms or multicellular parasites which infect human and non-human vertebrates, or against a cancer cell or tumor cell; and
(b) administering to the subject a recombinant adenoviral vector which does not comprise a ChAd157 fiber, or functional derivative thereof as described herein, the vector encoding second transgene encoding an immunogen which is useful to immunize a human or non-human animal against a different pathogen such as bacteria, fungi, parasitic microorganisms or multicellular parasites which infect human and non-human vertebrates, or against a cancer cell or tumor cell;
wherein steps (a) and (b) may be undertaken in either order.

### Claim 69 (depends on 4, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The recombinant adenoviral vector or method according to any one of claims 53 to 68, wherein the recombinant adenoviral vector which does not comprise a ChAd157 fiber, or functional derivative thereof as described herein has a low cross-reactivity with the recombinant adenoviral vector according to any one of claims 4 or 8 to 43.

### Claim 70 (depends on 69)

The recombinant adenoviral vector or method according to claim 69, wherein immunisation with a first vector elicits a neutralising titer which is on average less than 50% of the level arising from immunisation with the second vector.

### Claim 71 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The recombinant adenoviral vector or method according to any one of claims 53 to 70, wherein the recombinant adenoviral vector which does not comprise a ChAd157 fiber does not comprise a ChAd157 fiber, ChAd157 hexon or ChAd157 fiber or functional derivatives thereof having at least 98% identity thereto.
